Amneal Pharmaceuticals, Inc.
AMRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Amneal Pharmaceuticals, Inc. (AMRX) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $5.70B market cap, placing it firmly in the mid-cap category. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Market Cap
$5.70B
Beta
1.26
P/E (TTM)
48.24
P/E (Fwd)
15.93
EPS (TTM)
$0.37
EPS (Fwd)
$1.12
ROE
—
ROA
8.3%
Cash
$200.6M
Total Debt
$2.70B
Free CF
$101.5M
52W Change
124.0%
Annual Financials
Cash vs Debt
Amneal Pharmaceuticals, Inc. carries $2.70B in total debt against $200.6M in cash reserves — debt is roughly 13.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $101.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.21B (2022) to $3.02B (2025), reflecting a 36% increase over the period.
Amneal Pharmaceuticals, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing AMRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.